A month ago, there was no conclusive evidence in favour of booster shots of Covid-19 vaccines.Indeed, with no scientific basis, they appeared morally and ethically wrong in the face of vaccine inequity.
Although the moral and ethical dilemma persists, scientific data is increasingly favouring boosters. When compared to the protection provided by the AstraZeneca/Oxford vaccine against symptomatic Covid-19 caused by the Omicron variant of the Sars-CoV-2 virus, according to a recent study released Friday by the United Kingdom’s Health Security Agency, the standard two-dose regimen of the AstraZeneca/Oxford vaccine provided almost no protection against symptomatic Covid-19 caused by the Omicron variant of the Sars-CoV-2 virus (69 percent ).But a booster dose (of the same vaccine) increased their efficacy to 71%.
This is a preliminary and limited research, but it is grounded on reality. It’s also based on a vaccine whose Indian equivalent, Covishield, has formed the cornerstone of the country’s immunisation campaign. So far, India has fully immunised 55 percent of its adult population and partially vaccinated the other 31 percent. The economy has recovered, and most economic and mobility indexes have returned to pre-pandemic levels or higher. State elections are also looming in India, especially in the state of Uttar Pradesh.
Except for the vaccination benefits and the scale of the recovery, the country is presently in a similar position to where it was in February, shortly before the bruising second wave. This is the ideal time for India to authorise (or perhaps compel) booster doses, as well as arrange advance orders with Covishield manufacturer Serum Institute, which has stated that it is considering halving output. And now is the best moment to begin vaccination the 150 million young people aged 12 to 18. There should be no time lag here.
